Qlife Holding (QLIFE.ST) Stock Analysis & AI Equity Report
Qlife Holding (QLIFE.ST) overview
Qlife Holding (QLIFE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Qlife Holding reported revenue of SEK 0.3m and operating profit of SEK -19.4m; the year-end share price was 2.84 SEK and market capitalisation was SEK 35.6m. Qlife Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Qlife Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Qlife Holding
Qlife Holding AB develops and commercializes the Egoo.health platform, a home-based biomarker testing system that uses a small blood sample to measure and analyze health markers. The company focuses on point-of-care diagnostics for chronic disease monitoring and related clinical applications, and it also works through partnerships on development, regulatory approval, manufacturing, and commercialization.
Generate the Qlife Holding report
Qlife Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Qlife Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.